Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 160
Filtrar
Más filtros

Medicinas Complementárias
Tipo del documento
Intervalo de año de publicación
1.
Nutrients ; 16(4)2024 Feb 10.
Artículo en Inglés | MEDLINE | ID: mdl-38398830

RESUMEN

The escalating prevalence of metabolic and cardiometabolic disorders, often characterized by oxidative stress and chronic inflammation, poses significant health challenges globally. As the traditional therapeutic approaches may sometimes fall short in managing these health conditions, attention is growing toward nutraceuticals worldwide; with compounds being obtained from natural sources with potential therapeutic beneficial effects being shown to potentially support and, in some cases, replace pharmacological treatments, especially for individuals who do not qualify for conventional pharmacological treatments. This review delves into the burgeoning field of nutraceutical-based pharmacological modulation as a promising strategy for attenuating oxidative stress and inflammation in metabolic and cardiometabolic disorders. Drawing from an extensive body of research, the review showcases various nutraceutical agents, such as polyphenols, omega-3 fatty acids, and antioxidants, which exhibit antioxidative and anti-inflammatory properties. All these can be classified as novel nutraceutical-based drugs that are capable of regulating pathways to mitigate oxidative-stress- and inflammation-associated metabolic diseases. By exploring the mechanisms through which nutraceuticals interact with oxidative stress pathways and immune responses, this review highlights their potential to restore redox balance and temper chronic inflammation. Additionally, the challenges and prospects of nutraceutical-based interventions are discussed, encompassing bioavailability enhancement, personalized treatment approaches, and clinical translation. Through a comprehensive analysis of the latest scientific reports, this article underscores the potential of nutraceutical-based pharmacological treatment modulation as a novel avenue to fight oxidative stress and inflammation in the complex landscape of metabolic disorders, particularly accentuating their impact on cardiovascular health.


Asunto(s)
Enfermedades Cardiovasculares , Enfermedades Metabólicas , Humanos , Suplementos Dietéticos , Estrés Oxidativo , Antioxidantes/farmacología , Inflamación/metabolismo , Enfermedades Metabólicas/prevención & control , Enfermedades Metabólicas/tratamiento farmacológico , Enfermedades Cardiovasculares/prevención & control , Enfermedades Cardiovasculares/tratamiento farmacológico
2.
J Nutr Biochem ; 124: 109533, 2024 02.
Artículo en Inglés | MEDLINE | ID: mdl-37977406

RESUMEN

The prevalences of diabetes mellitus and obesity are increasing yearly and has become a serious social burden. In addition to genetic factors, environmental factors in early life development are critical in influencing the prevalence of metabolic disorders in offspring. A growing body of evidence suggests the critical role of early methyl donor intervention in offspring health. Emerging studies have shown that methyl donors can influence offspring metabolism through epigenetic modifications and changing metabolism-related genes. In this review, we focus on the role of folic acid, betaine, vitamin B12, methionine, and choline in protecting against metabolic disorders in offspring. To address the current evidence on the potential role of maternal methyl donors, we summarize clinical studies as well as experimental animal models that support the impact of maternal methyl donors on offspring metabolism and discuss the mechanisms of action that may bring about these positive effects. Given the worldwide prevalence of metabolic disorders, these findings could be utilized in clinical practice, in which methyl donor supplementation in the early life years may reverse metabolic disorders in offspring and block the harmful intergenerational effect.


Asunto(s)
Suplementos Dietéticos , Enfermedades Metabólicas , Animales , Betaína/farmacología , Betaína/uso terapéutico , Metilación de ADN , Ácido Fólico/farmacología , Ácido Fólico/uso terapéutico , Enfermedades Metabólicas/prevención & control , Humanos , Femenino , Embarazo
3.
Biol Trace Elem Res ; 201(5): 2222-2239, 2023 May.
Artículo en Inglés | MEDLINE | ID: mdl-35771339

RESUMEN

The application of natural and synthetic boron-containing compounds (BCC) in biomedical field is expanding. BCC have effects in the metabolism of living organisms. Some boron-enriched supplements are marketed as they exert effects in the bone and skeletal muscle; but also, BCC are being reported as acting on the enzymes and transporters of membrane suggesting they could modify the carbohydrate metabolism linked to some pathologies of high global burden, as an example is diabetes mellitus. Also, some recent findings are showing effects of BCC on lipid metabolism. In this review, information regarding the effects and interaction of these compounds was compiled, as well as the potential application for treating human metabolic disorders is suggested.


Asunto(s)
Boro , Enfermedades Metabólicas , Humanos , Boro/uso terapéutico , Compuestos de Boro/uso terapéutico , Compuestos de Boro/farmacología , Metabolismo de los Lípidos , Enfermedades Metabólicas/diagnóstico , Enfermedades Metabólicas/tratamiento farmacológico , Enfermedades Metabólicas/prevención & control
4.
J Ethnopharmacol ; 302(Pt A): 115700, 2023 Feb 10.
Artículo en Inglés | MEDLINE | ID: mdl-36126782

RESUMEN

ETHNOPHARMACOLOGICAL RELEVANCE: Obesity is a critical threat to global health, and brown adipose tissue (BAT) is a potential target for the treatment of obesity and comorbidities. Xuezhikang Capsule (XZK), an extract of red yeast rice, has remarkable clinical efficacy and is widely used for the treatment of hyperlipidemia and coronary heart disease. However, its modulatory effect on BAT remains unknown. AIM OF THIS STUDY: The aim of this study was to investigate the protective mechanism of XZK in the obese spontaneously hypertensive rat (SHR) model by evaluating the regulatory effect of XZK on the BAT gene profile through transcriptome sequencing. MATERIALS AND METHODS: The SHRs were randomly divided into four groups: the standard chow diet (STD) group, the STD supplemented with 126 mg/kg of XZK group, the high-fat diet (HFD) group, and the HFD supplemented with 126 mg/kg of XZK group. All SHRs were fed for 18 weeks. The metabolic phenotypes, including body weight, fat mass, oral glucose tolerance test (OGTT), and serum glucose and lipid levels, was evaluated, and hematoxylin and eosin staining (H&E) staining was performed to evaluate the adipose tissue histopathological phenotype. Transcriptome sequencing was performed to determine the mechanism by which XZK improves the metabolic phenotype and the expression of key differential expression genes was verified by real-time quantitative polymerase chain reaction (qRT-PCR). RESULTS: XZK inhibited HFD-induced weight gain and adipose tissue remodeling in SHRs and prevented hypertrophy of epididymal adipocytes and maintained the brown fat phenotype. XZK intervention also improved glucose and lipid metabolism in SHRs, as suggested by a reduction in serum triglyceride (TG), low-density cholesterol (LDL-C), and fasting blood glucose (FBG) levels as well as increasing in serum high-density cholesterol (HDL-C) levels. Transcriptome sequencing analysis confirmed the regulatory effect of XZK on the gene expression profile of BAT, and the expression patterns of 45 genes were reversed by the XZK intervention. Additionally, the results of the transcriptome analysis of 10 genes that are important for brown fat function were in line with the results of qRT-PCR. CONCLUSIONS: XZK protected SHRs from HFD-induced obesity, inhibited fat accumulation and improved glucolipid metabolism. Additionally, the protective effect of XZK on the overall metabolism of obese SHRs might partly be related to its regulatory effect on the BAT gene expression profile. These findings might provide novel therapeutic strategies for obesity-related metabolic diseases in traditional Chinese medicine (TCM).


Asunto(s)
Medicamentos Herbarios Chinos , Obesidad , Animales , Ratas , Tejido Adiposo Pardo/efectos de los fármacos , Tejido Adiposo Pardo/metabolismo , Colesterol , Dieta Alta en Grasa , Glucosa , Enfermedades Metabólicas/prevención & control , Ratones Endogámicos C57BL , Obesidad/complicaciones , Obesidad/tratamiento farmacológico , Obesidad/metabolismo , Ratas Endogámicas SHR , Transcriptoma , Medicamentos Herbarios Chinos/farmacología , Modelos Animales de Enfermedad , Humanos , Ratones
5.
Nutrients ; 14(24)2022 Dec 19.
Artículo en Inglés | MEDLINE | ID: mdl-36558557

RESUMEN

The effective prevention and treatment of cardiovascular and metabolic diseases is a major task for health systems since these pathological conditions are still major causes of mortality, morbidity, and disability worldwide [...].


Asunto(s)
Enfermedades Cardiovasculares , Sistema Cardiovascular , Enfermedades Metabólicas , Humanos , Enfermedades Cardiovasculares/prevención & control , Enfermedades Metabólicas/prevención & control , Suplementos Dietéticos
6.
Front Biosci (Landmark Ed) ; 27(9): 253, 2022 08 31.
Artículo en Inglés | MEDLINE | ID: mdl-36224002

RESUMEN

SIRT1 was discovered in 1979 but growing interest in this protein occurred only 20 years later when its overexpression was reported to prolong the lifespan of yeast. Since then, several studies have shown the benefits of its increased expression in preventing or delaying of many diseases. SIRT1, as a histone deacetylase, is an epigenetic regulator but it has wide range of non-histone targets which are involved in metabolism, energy sensing pathways, circadian machinery and in inflammatory regulation. Disturbances in these interconnected processes cause different diseases, however it seems they have common roots in unbalanced inflammatory processes and lower level or inactivation of SIRT1. SIRT1 inactivation was implicated in coronavirus disease (COVID-19) severity as well and its low level counted as a predictor of uncontrolled COVID-19. Several other diseases such as metabolic disease, obesity, diabetes, Alzheimer's disease, cardiovascular disease or depression are related to chronic inflammation and similarly show decreased SIRT1 level. It has recently been known that SIRT1 is inducible by calorie restriction/proper diet, physical activity and appropriate emotional state. Indeed, a healthier metabolic state belongs to higher level of SIRT1 expression. These suggest that appropriate lifestyle as non-pharmacological treatment may be a beneficial tool in the prevention of inflammation or metabolic disturbance-related diseases as well as could be a part of the complementary therapy in medical practice to reach better therapeutic response and quality of life. We aimed in this review to link the beneficial effect of SIRT1 with those diseases, where its level decreased. Moreover, we aimed to collect evidences of interventions or treatments, which increase SIRT1 expression and thus, open the possibility to use them as preventive or complementary therapies in medical practice.


Asunto(s)
Epigénesis Genética , Enfermedades Metabólicas , Neoplasias , Sirtuina 1 , COVID-19 , Homeostasis , Humanos , Inflamación , Enfermedades Metabólicas/genética , Enfermedades Metabólicas/prevención & control , Neoplasias/genética , Neoplasias/prevención & control , Calidad de Vida , Sirtuina 1/genética , Sirtuina 1/metabolismo
7.
Curr Opin Clin Nutr Metab Care ; 25(6): 436-442, 2022 11 01.
Artículo en Inglés | MEDLINE | ID: mdl-35943130

RESUMEN

PURPOSE OF REVIEW: This review aims to discuss the potential roles of omega-3 (ω-3) and omega-6 (ω-6) polyunsaturated fatty acids (PUFAs) in the prevention and treatment of metabolic diseases, to provide the latest evidence from epidemiological and clinical studies, and to highlight novel insights into this field. RECENT FINDINGS: Higher dietary or circulating ω-3 PUFA levels are related to a lower risk of metabolic syndrome. Novel findings in obesity indicate higher proportions of ω-6 and ω-3 PUFAs, a modulated oxylipin profile and an altered transcriptome in subcutaneous white adipose tissue, that seem resistant to the effects of ω-3 PUFAs compared with what occurs in normal weight individuals. ω-3 PUFAs may improve the blood lipid profile and glycemic outcomes in patients with type 2 diabetes mellitus and reduce liver fat in nonalcoholic fatty liver disease (NAFLD); the findings of several recent meta-analyses support these effects. Genetic background affects inter-individual variability in the insulin sensitivity response to ω-3 PUFA supplementation. ω-3 PUFAs have prebiotic effects, altering the gut microbiota. SUMMARY: Although evidence for health benefits of ω-3 PUFAs is strong, recent findings suggest a more personalized approach to ω-3 PUFA intake for individuals at high risk for metabolic diseases.


Asunto(s)
Diabetes Mellitus Tipo 2 , Ácidos Grasos Omega-3 , Enfermedades Metabólicas , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Diabetes Mellitus Tipo 2/genética , Ácidos Grasos Omega-3/farmacología , Ácidos Grasos Omega-3/uso terapéutico , Ácidos Grasos Insaturados , Humanos , Lípidos , Enfermedades Metabólicas/tratamiento farmacológico , Enfermedades Metabólicas/prevención & control , Oxilipinas
8.
Adv Nutr ; 13(3): 833-845, 2022 06 01.
Artículo en Inglés | MEDLINE | ID: mdl-35167660

RESUMEN

This review summarizes the latest findings, from animal models and clinical studies, regarding the cardiovascular and metabolic consequences in adult life of zinc deficiency (ZD) during prenatal and early postnatal life. The effect of zinc supplementation (ZS) and new insights about sex differences in the phenotype and severity of cardiovascular and metabolic alterations are also discussed. Zinc has antioxidant, anti-inflammatory, and antiapoptotic properties and regulates the activity of enzymes involved in regulation of the metabolic, cardiovascular, and renal systems. Maternal ZD is associated with intrauterine growth restriction and low birth weight (LBW). Breast-fed preterm infants are at risk of ZD due to lower zinc uptake during fetal life and reduced gut absorption capacity. ZS is most likely to increase growth in preterm infants and survival in LBW infants in countries where ZD is prevalent. Studies performed in rats revealed that moderate ZD during prenatal and/or early postnatal growth is a risk factor for the development of hypertension, cardiovascular and renal alterations, obesity, and diabetes in adult life. An adequate zinc diet during postweaning life does not always prevent the cardiovascular and metabolic alterations induced by zinc restriction during fetal and lactation periods. Male rats are more susceptible to this injury than females, and some of the mechanisms involved include: 1) alterations in organogenesis, 2) activation of oxidative, apoptotic, and inflammatory processes, 3) dysfunction of nitric oxide and renin-angiotensin-aldosterone systems, 4) changes in glucose and lipid metabolism, and 5) adipose tissue dysfunction. Safeguarding body zinc requirements during pregnancy, lactation, and growth periods could become a new target in the prevention and treatment of cardiovascular and metabolic disorders. Further research is needed to elucidate the efficacy of ZS during early stages of growth to prevent the development of these diseases later in life.


Asunto(s)
Enfermedades Cardiovasculares , Desnutrición , Enfermedades Metabólicas , Efectos Tardíos de la Exposición Prenatal , Animales , Femenino , Humanos , Recién Nacido , Recien Nacido Prematuro , Masculino , Enfermedades Metabólicas/etiología , Enfermedades Metabólicas/prevención & control , Embarazo , Ratas , Ratas Wistar , Vitaminas , Zinc
9.
Eat Weight Disord ; 27(4): 1415-1425, 2022 May.
Artículo en Inglés | MEDLINE | ID: mdl-34370270

RESUMEN

PURPOSE: Time-restricted feeding (TRF) reverses obesity and insulin resistance, yet the central mechanisms underlying its beneficial effects are not fully understood. Recent studies suggest a critical role of hypothalamic galanin and its receptors in the regulation of energy balance. It is yet unclear whether TRF could regulate the expression of galanin and its receptors in the hypothalamus of mice fed a high-fat diet. METHODS: To test this effect, we subjected mice to either ad lib or TRF of a high-fat diet for 8 h per day. After 4 weeks, galanin and many neuropeptides associated with the function of metabolism were examined. RESULTS: The present findings showed that mice under TRF consume equivalent calories from a high-fat diet as those with ad lib access, yet are protected against obesity and have improved glucose metabolism. Plasma galanin, orexin A, irisin and adropin levels were significantly reversed by TRF regimen. Besides, TRF regimen reversed the progression of metabolic disorders in mice by increasing GLUT4 and PGC-1α expression in skeletal muscles. Moreover, the levels of galanin and GALR1 expression were severely diminished in the hypothalamus of the TRF mice, whereas GALR2 was highly expressed. CONCLUSIONS: TRF diminished galanin and GALR1 expression, and increased GALR2 expression in the hypothalamus of mice fed a high-fat diet. The current studies provide additional evidence that TRF is effective in improving HFD-induced hyperglycemia and insulin resistance in mice, and this effect could be associated with TRF-induced changes of the galanin systems in the hypothalamus. LEVEL OF EVIDENCE: No level of evidence, animal studies.


Asunto(s)
Galanina/metabolismo , Resistencia a la Insulina , Enfermedades Metabólicas , Receptor de Galanina Tipo 1/metabolismo , Animales , Galanina/farmacología , Humanos , Hipotálamo/metabolismo , Enfermedades Metabólicas/metabolismo , Enfermedades Metabólicas/prevención & control , Ratones , Ratones Endogámicos C57BL , Obesidad/metabolismo
10.
Pharmacol Res ; 175: 106029, 2022 01.
Artículo en Inglés | MEDLINE | ID: mdl-34896248

RESUMEN

The leaves of Morus alba L. (called Sangye in Chinese, ML), which belong to the genus Morus., are highly valuable edible plants in nutrients and nutraceuticals. In Asian countries including China, Japan and Korea, ML are widely used as functional foods including beverages, noodles and herbal tea because of its biological and nutritional value. Meanwhile, ML-derived products in the form of powders, extracts and capsules are widely consumed as dietary supplements for controlling blood glucose and sugar. Clinical studies showed that ML play an important role in the treatment of metabolic diseases including the diabetes, dyslipidemia, obesity, atherosclerosis and hypertension. People broadly use ML due to their nutritiousness, deliciousness, safety, and abundant active benefits. However, the systematic pharmacological mechanisms of ML on metabolic diseases have not been fully revealed. Therefore, in order to fully utilize and scale relevant products about ML, this review summarizes the up-to-date information about the ML and its constituents effecting on metabolic disease.


Asunto(s)
Enfermedades Metabólicas/tratamiento farmacológico , Morus , Preparaciones de Plantas/uso terapéutico , Animales , Etnobotánica , Humanos , Enfermedades Metabólicas/metabolismo , Enfermedades Metabólicas/prevención & control , Fitoterapia , Hojas de la Planta , Preparaciones de Plantas/química , Preparaciones de Plantas/farmacología
11.
Nutrients ; 13(12)2021 Dec 11.
Artículo en Inglés | MEDLINE | ID: mdl-34959992

RESUMEN

In recent years, epidemiological studies have suggested that metabolic disorders are nutritionally dependent. A healthy diet that is rich in polyphenols may be beneficial in the treatment of metabolic diseases such as polycystic ovary syndrome, metabolic syndrome, non-alcoholic fatty liver disease, cardiovascular disease, and, in particular, atherosclerosis. Curcumin is a polyphenol found in turmeric and has been reported to have antioxidant, anti-inflammatory, hepatoprotective, anti-atherosclerotic, and antidiabetic properties, among others. This review summarizes the influence of supplementation with curcumin on metabolic parameters in selected metabolic disorders.


Asunto(s)
Curcumina/administración & dosificación , Curcumina/farmacología , Suplementos Dietéticos , Enfermedades Metabólicas/tratamiento farmacológico , Fitoterapia , Antiinflamatorios , Antioxidantes , Aterosclerosis/tratamiento farmacológico , Aterosclerosis/prevención & control , Enfermedades Cardiovasculares/tratamiento farmacológico , Enfermedades Cardiovasculares/prevención & control , Curcuma/química , Curcumina/aislamiento & purificación , Femenino , Humanos , Hipoglucemiantes , Masculino , Enfermedades Metabólicas/prevención & control , Enfermedad del Hígado Graso no Alcohólico/tratamiento farmacológico , Síndrome del Ovario Poliquístico/tratamiento farmacológico
12.
J Oleo Sci ; 70(12): 1707-1717, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34866108

RESUMEN

Oils and lipids are common food components and efficient sources of energy. Both the quantity and the quality of oils and lipids are important with regard to health and disease. Fatty acid ester of hydroxy fatty acid (FAHFA) is a novel lipid class that was discovered as an endogenous lipid; FAHFAs have shown anti-diabetic effects in a mammalian system. We analyzed the overall FAHFA composition in nut oils and other common oils: almond (raw, roasted), walnut, peanut, olive, palm, soybean, and rapeseed oils. We developed a method of liquid chromatography coupled with electrospray ionization triple quadrupole mass spectrometry (LC-ESI/MS/MS) for a comprehensive target analysis of FAHFAs. The analysis revealed wide variation in the FAHFA profiles (15 compounds and 62 peaks). For 7-11 compounds of FAHFA, a total level of 8-29 pmol/mg oil was detected in nuts oils; for 11 compounds, 4.9 pmol/mg oil was detected in olive oil, and for 4-9 compounds, < 2 pmol/mg oil was detected in palm, soy, and rapeseed oils. The major FAHFAs were FAHFA 36:3, FAHFA 36:2, and FAHFA 36:4 in nut oil, FAHFA 36:2, FAHFA 34:1, and FAHFA 36:1 in olive oil, and FAHFA 32:1, FAHFA 34:0, FAHFA 36:0, and FAHFA 36:1 in all of the common oils. The composition of FAHFAs in nut oils is mainly unsaturated fatty acids, whereas those in olive oil are unsaturated fatty acids and saturated fatty acids. The composition of FAHFAs in common oils was mainly saturated fats. This is the first report to demonstrate the quality and quantity of the FAHFAs in the nut oils. Nuts have been described to be a great source of many nutrients and to be beneficial for our health. Our present findings comprise additional evidence that the intake of nuts in daily diets may prevent metabolic and inflammatory-based diseases.


Asunto(s)
Ésteres/análisis , Ácidos Grasos Insaturados/análisis , Análisis de los Alimentos , Calidad de los Alimentos , Nueces/química , Aceites de Plantas/química , Cromatografía Liquida/métodos , Ingestión de Alimentos , Ácidos Grasos Insaturados/farmacología , Hidroxilación , Hipoglucemiantes , Inflamación/prevención & control , Enfermedades Metabólicas/prevención & control , Espectrometría de Masa por Ionización de Electrospray/métodos , Espectrometría de Masas en Tándem/métodos
13.
Front Immunol ; 12: 774433, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34868039

RESUMEN

Background: Studies have shown that gut microbe disorder in mice due to early-life antibiotic exposure promotes glycolipid metabolism disorder in adulthood. However, the underlying mechanism remains unclear and there is not yet an effective intervention or treatment for this process. Purpose: The study investigated whether early-life azithromycin (AZT) exposure in mice could promote high-fat diet (HFD)-induced glycolipid metabolism disorder in adulthood. Moreover, the effect of citrus reticulata pericarpium (CRP) extract on glycolipid metabolism disorder via regulation of gut microbiome in mice exposed to antibodies early in life were investigated. Methods and Results: Three-week-old mice were treated with AZT (50 mg/kg/day) via drinking water for two weeks and then were fed a CRP diet (1% CRP extract) for four weeks and an HFD for five weeks. The results showed that early-life AZT exposure promoted HFD-induced glycolipid metabolism disorder, increased the levels of inflammatory factors, promoted the flora metabolism product trimethylamine N-oxide (TMAO), and induced microbial disorder in adult mice. Importantly, CRP extract mitigated these effects. Conclusion: Taken together, these findings suggest that early-life AZT exposure increases the susceptibility to HFD-induced glycolipid metabolism disorder in adult mice, and CRP extract can decrease this susceptibility by regulating gut microbiome.


Asunto(s)
Citrus/química , Glucolípidos/metabolismo , Metabolismo de los Lípidos/efectos de los fármacos , Enfermedades Metabólicas/etiología , Enfermedades Metabólicas/metabolismo , Extractos Vegetales/farmacología , Animales , Antibacterianos/efectos adversos , Azitromicina/efectos adversos , Biomarcadores , Cromatografía Líquida de Alta Presión , Dieta Alta en Grasa/efectos adversos , Modelos Animales de Enfermedad , Susceptibilidad a Enfermedades , Prueba de Tolerancia a la Glucosa , Mediadores de Inflamación/sangre , Masculino , Enfermedades Metabólicas/diagnóstico , Enfermedades Metabólicas/prevención & control , Ratones , Extractos Vegetales/química , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción
14.
J Am Heart Assoc ; 10(24): e023227, 2021 12 21.
Artículo en Inglés | MEDLINE | ID: mdl-34873915

RESUMEN

Background The complexity of the interaction between metabolic dysfunction and cardiovascular complications has long been recognized to extend beyond simple perturbations of blood glucose levels. Yet, structured interventions targeting the root pathologies are not forthcoming. Growing evidence implicates the inflammatory changes occurring in perivascular adipose tissue (PVAT) as early instigators of cardiovascular deterioration. Methods and Results We used a nonobese prediabetic rat model with localized PVAT inflammation induced by hypercaloric diet feeding, which dilutes inorganic phosphorus (Pi) to energy ratio by 50%, to investigate whether Pi supplementation ameliorates the early metabolic impairment. A 12-week Pi supplementation at concentrations equivalent to and twice as much as that in the control diet was performed. The localized PVAT inflammation was reversed in a dose-dependent manner. The increased expression of UCP1 (uncoupling protein1), HIF-1α (hypoxia inducible factor-1α), and IL-1ß (interleukin-1ß), representing the hallmark of PVAT inflammation in this rat model, were reversed, with normalization of PVAT macrophage polarization. Pi supplementation restored the metabolic efficiency consistent with its putative role as an UCP1 inhibitor. Alongside, parasympathetic autonomic and cerebrovascular dysfunction function observed in the prediabetic model was reversed, together with the mitigation of multiple molecular and histological cardiovascular damage markers. Significantly, a Pi-deficient control diet neither induced PVAT inflammation nor cardiovascular dysfunction, whereas Pi reinstatement in the diet after a 10-week exposure to a hypercaloric low-Pi diet ameliorated the dysfunction. Conclusions Our present results propose Pi supplementation as a simple intervention to reverse PVAT inflammation and its early cardiovascular consequences, possibly through the interference with hypercaloric-induced increase in UCP1 expression/activity.


Asunto(s)
Tejido Adiposo , Suplementos Dietéticos , Inflamación , Fósforo , Tejido Adiposo/metabolismo , Tejido Adiposo/patología , Animales , Enfermedades Cardiovasculares/etiología , Enfermedades Cardiovasculares/prevención & control , Inflamación/complicaciones , Inflamación/prevención & control , Enfermedades Metabólicas/prevención & control , Fósforo/uso terapéutico , Estado Prediabético , Ratas
15.
Curr Drug Metab ; 22(13): 1017-1034, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34825869

RESUMEN

The N-3 polyunsaturated fatty acids (PUFAs) have a wide range of health benefits, including antiinflammatory effects, improvements in lipids metabolism and promoting insulin secretion, as well as reduction of cancer risk. Numerous studies support that N-3 PUFAs have the potentials to improve many metabolic diseases, such as diabetes, nonalcoholic fatty liver disease and obesity, which are attributable to N-3 PUFAs mediated enhancement of insulin secretion by pancreatic ß-cells and improvements in insulin sensitivity and metabolic disorders in peripheral insulin-sensitive tissues such as liver, muscles, and adipose tissue. In this review, we summarized the up-to-date clinical and basic studies on the regulatory effects and molecular mechanisms of N-3 PUFAs mediated benefits on pancreatic ß-cells, adipose tissue, liver, and muscles in the context of glucose and/or lipid metabolic disorders. We also discussed the potential factors involved in the inconsistent results from different clinical researches of N-3 PUFAs.


Asunto(s)
Ácidos Docosahexaenoicos/farmacología , Ácido Eicosapentaenoico/farmacología , Células Secretoras de Insulina , Insulina , Metabolismo de los Lípidos/efectos de los fármacos , Enfermedades Metabólicas , Animales , Ácidos Grasos Omega-3/metabolismo , Ácidos Grasos Omega-3/farmacología , Humanos , Insulina/biosíntesis , Insulina/metabolismo , Resistencia a la Insulina/fisiología , Células Secretoras de Insulina/efectos de los fármacos , Células Secretoras de Insulina/metabolismo , Enfermedades Metabólicas/clasificación , Enfermedades Metabólicas/metabolismo , Enfermedades Metabólicas/prevención & control
16.
Nutrients ; 13(9)2021 Aug 27.
Artículo en Inglés | MEDLINE | ID: mdl-34578869

RESUMEN

Children with obesity are at higher risk for developing cardiometabolic diseases that once were considered health conditions of adults. Obesity is commonly associated with cardiometabolic risk factors such as dyslipidemia, hyperglycemia, hyperinsulinemia and hypertension that contribute to the development of endothelial dysfunction. Endothelial dysfunction, characterized by reduced nitric oxide (NO) production, precedes vascular abnormalities including atherosclerosis and arterial stiffness. Thus, early detection and treatment of cardiometabolic risk factors are necessary to prevent deleterious vascular consequences of obesity at an early age. Non-pharmacological interventions including L-Citrulline (L-Cit) supplementation and aerobic training stimulate endothelial NO mediated vasodilation, leading to improvements in organ perfusion, blood pressure, arterial stiffness, atherosclerosis and metabolic health (glucose control and lipid profile). Few studies suggest that the combination of L-Cit supplementation and exercise training can be an effective strategy to counteract the adverse effects of obesity on vascular function in older adults. Therefore, this review examined the efficacy of L-Cit supplementation and aerobic training interventions on vascular and metabolic parameters in obese individuals.


Asunto(s)
Enfermedades Cardiovasculares/prevención & control , Citrulina/administración & dosificación , Ejercicio Físico , Longevidad , Enfermedades Metabólicas/prevención & control , Obesidad/terapia , Adolescente , Adulto , Anciano , Arginina/metabolismo , Aterosclerosis/prevención & control , Presión Sanguínea/efectos de los fármacos , Factores de Riesgo Cardiometabólico , Niño , Suplementos Dietéticos , Endotelio Vascular/efectos de los fármacos , Femenino , Humanos , Hipertensión/prevención & control , Masculino , Persona de Mediana Edad , Óxido Nítrico/metabolismo , Obesidad/fisiopatología , Rigidez Vascular/efectos de los fármacos , Vasodilatación/efectos de los fármacos , Adulto Joven
17.
Nutrients ; 13(7)2021 Jun 22.
Artículo en Inglés | MEDLINE | ID: mdl-34206176

RESUMEN

Energy restriction is a first therapy in the treatment of obesity, but the underlying biological mechanisms have not been completely clarified. We analyzed the effects of restriction of high-fat diet (HFD) on weight loss, circulating gut hormone levels and expression of hypothalamic neuropeptides. Ten-week-old male Wistar rats (n = 40) were randomly distributed into four groups: two fed ad libitum a normal diet (ND) (N group) or a HFD (H group) and two subjected to a 25% caloric restriction of ND (NR group) or HFD (HR group) for 9 weeks. A 25% restriction of HFD over 9 weeks leads to a 36% weight loss with regard to the group fed HFD ad libitum accompanied by normal values in adiposity index and food efficiency ratio (FER). This restriction also carried the normalization of NPY, AgRP and POMC hypothalamic mRNA expression, without changes in CART. Caloric restriction did not succeed in improving glucose homeostasis but reduced HFD-induced hyperinsulinemia. In conclusion, 25% restriction of HFD reduced adiposity and improved metabolism in experimental obesity, without changes in glycemia. Restriction of the HFD triggered the normalization of hypothalamic NPY, AgRP and POMC expression, as well as ghrelin and leptin levels.


Asunto(s)
Restricción Calórica/métodos , Dieta con Restricción de Grasas/métodos , Enfermedades Metabólicas/prevención & control , Neuropéptidos/metabolismo , Obesidad/dietoterapia , Adiposidad/fisiología , Proteína Relacionada con Agouti/metabolismo , Animales , Dieta Alta en Grasa/efectos adversos , Grasas de la Dieta/administración & dosificación , Modelos Animales de Enfermedad , Ingestión de Alimentos/fisiología , Ghrelina/metabolismo , Hipotálamo/metabolismo , Leptina/metabolismo , Masculino , Enfermedades Metabólicas/etiología , Neuropéptido Y/metabolismo , Obesidad/complicaciones , Proopiomelanocortina/metabolismo , Ratas , Ratas Wistar , Pérdida de Peso/fisiología
18.
Mar Drugs ; 19(6)2021 May 26.
Artículo en Inglés | MEDLINE | ID: mdl-34073184

RESUMEN

Euphausia superba, commonly known as krill, is a small marine crustacean from the Antarctic Ocean that plays an important role in the marine ecosystem, serving as feed for most fish. It is a known source of highly bioavailable omega-3 polyunsaturated fatty acids (eicosapentaenoic acid and docosahexaenoic acid). In preclinical studies, krill oil showed metabolic, anti-inflammatory, neuroprotective and chemo preventive effects, while in clinical trials it showed significant metabolic, vascular and ergogenic actions. Solvent extraction is the most conventional method to obtain krill oil. However, different solvents must be used to extract all lipids from krill because of the diversity of the polarities of the lipid compounds in the biomass. This review aims to provide an overview of the chemical composition, bioavailability and bioaccessibility of krill oil, as well as the mechanisms of action, classic and non-conventional extraction techniques, health benefits and current applications of this marine crustacean.


Asunto(s)
Antiinflamatorios , Antineoplásicos , Suplementos Dietéticos , Euphausiacea , Ácidos Grasos Omega-3 , Aceites de Pescado/química , Fármacos Neuroprotectores , Animales , Antiinflamatorios/farmacocinética , Antiinflamatorios/farmacología , Antiinflamatorios/uso terapéutico , Antineoplásicos/farmacocinética , Antineoplásicos/farmacología , Antineoplásicos/uso terapéutico , Ejercicio Físico , Ácidos Grasos Omega-3/farmacocinética , Ácidos Grasos Omega-3/farmacología , Ácidos Grasos Omega-3/uso terapéutico , Aceites de Pescado/farmacología , Microbioma Gastrointestinal/efectos de los fármacos , Humanos , Enfermedades Inflamatorias del Intestino/dietoterapia , Enfermedades Inflamatorias del Intestino/prevención & control , Enfermedades Metabólicas/dietoterapia , Enfermedades Metabólicas/prevención & control , Fármacos Neuroprotectores/farmacocinética , Fármacos Neuroprotectores/farmacología , Fármacos Neuroprotectores/uso terapéutico
19.
Sci Rep ; 11(1): 5099, 2021 03 03.
Artículo en Inglés | MEDLINE | ID: mdl-33658635

RESUMEN

With increased global warming, the impact of high temperature and humidity (HTH) on human health is increasing. Traditional Chinese medicine describes the Herb Yinchen as a remedy for reducing heat and eliminating dampness. This study focused on the impact of HTH conditions on mice and the potential protective effect of Herb Yinchen. Five male Balb/c mouse groups included two normal control groups, two HTH-exposed groups, and one Yinchen-treated group. For either three or ten days, normal and HTH-exposed mice were housed under normal or HTH (33 ± 2 °C,85% relative humidity) conditions, respectively. Yinchen-treated mice, housed under HTH conditions, received the Herb Yinchen decoction for three days. Metabolite profiles of plasma and liver samples from each group were analyzed using LC-MS/MS. Fecal DNA was extracted for 16S rDNA analysis to evaluate the intestinal microbiome. Spearman correlation analysis was performed on metabolites, bacteria, and bile acids that differed between the groups. We found that HTH altered the host metabolite profiles and reduced microbial diversity, causing intestinal microbiome imbalance. Interestingly, Herb Yinchen treatment improved HTH-mediated changes of the metabolite profiles and the intestinal microbiome, restoring them to values observed in normal controls. In conclusion, our study reveals that HTH causes intestinal bacterial disturbances and metabolic disorders in normal mice, while Herb Yinchen could afford protection against such changes.


Asunto(s)
ADN Ribosómico/genética , Medicamentos Herbarios Chinos/administración & dosificación , Disbiosis/etiología , Calor/efectos adversos , Humedad/efectos adversos , Enfermedades Metabólicas/etiología , Fitoterapia/métodos , Sustancias Protectoras/administración & dosificación , Espectrometría de Masas en Tándem/métodos , Animales , Artemisia , Cromatografía Liquida/métodos , Disbiosis/prevención & control , Heces/microbiología , Microbioma Gastrointestinal/efectos de los fármacos , Microbioma Gastrointestinal/genética , Masculino , Medicina Tradicional China/métodos , Enfermedades Metabólicas/prevención & control , Ratones , Ratones Endogámicos BALB C , Resultado del Tratamiento
20.
Lancet Gastroenterol Hepatol ; 6(3): 238-251, 2021 03.
Artículo en Inglés | MEDLINE | ID: mdl-33581762

RESUMEN

Obesity and the corresponding burden of related diseases is a major public health issue worldwide that is reaching pandemic proportions. Bariatric surgery is the only intervention that has been shown to result in substantial and lasting weight loss, and a decrease in overall mortality for patients with severe obesity. Consequently, the population of patients having undergone this procedure is increasing. Multifactorial weight-dependent and independent mechanisms underlying metabolic diseases could also drive preventable, but potentially life-threatening, long-term nutritional complications. However, given post-bariatric patients are prone to functional gastrointestinal symptoms and substantial weight loss, nutritional complications might be challenging. This Review is focused on the prevention and treatment of nutritional complications after bariatric surgery in the clinical setting.


Asunto(s)
Cirugía Bariátrica/efectos adversos , Desnutrición/epidemiología , Enfermedades Metabólicas/prevención & control , Obesidad Mórbida/cirugía , Cirugía Bariátrica/métodos , Femenino , Enfermedades Gastrointestinales/etiología , Humanos , Desnutrición/etiología , Desnutrición/fisiopatología , Obesidad Mórbida/complicaciones , Obesidad Mórbida/epidemiología , Complicaciones Posoperatorias/epidemiología , Complicaciones Posoperatorias/fisiopatología , Pérdida de Peso
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA